ORPHA:420566
Bleeding disorder due to CalDAG-GEFI deficiency
Also known as: Bleeding disorder due to calcium- and DAG-regulated guanine exchange factor-1 deficiency
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
17
34.8th percentile
Trials
0
Interventional, condition-specific
Researchers
130
Distinct authors in sample
Gene link
RASGRP2
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Bleeding disorder due to CalDAG-GEFI deficiency is a rare hematologic disease due to defective platelet function and characterized by mucocutaneous bleeding starting in infancy (around 18 months of age), presenting with prolonged and severe epistaxis, hematomas and bleeding after tooth extraction. Massive menorrhagia and chronic anemia have also been reported.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014386
- OMIM:615888
- UMLS:C4014584
Additional Mondo synonyms (7)
BDPLT18 · RASGRP2 inherited bleeding disorder, platelet-type · RASGRP2-related platelet disorder · bleeding disorder due to CalDAG-GEFI deficiency · bleeding disorder due to calcium- and DAG-regulated guanine exchange factor-1 deficiency · inherited bleeding disorder, platelet-type caused by mutation in RASGRP2 · platelet-type bleeding disorder 18
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — RASGRP2
- LiteraturePresent
17 matched papers (17 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (RASGRP2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
17
17 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
17 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
17 in the last 10 years · high confidence · 34.8th percentile (publications denominator)
Phrase hits: 17 · MeSH hits: 0
Who's working on it?
130
Distinct author names in 17 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bastida JM3 papers · 2025
Department of Hematology, Instituto de Investigación Biomédica de Salamanca (IBSAL), Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain.
Papers in Europe PMC - 02Rivera J3 papers · 2025
Department of Hematology and Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER-U765, 30008 Murcia, Spain.
Papers in Europe PMC - 03Bury L2 papers · 2024
Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Papers in Europe PMC - 04Downes K2 papers · 2024
Department of Haematology, University of Cambridge, Cambridge, UK.
Papers in Europe PMC - 05Freson K2 papers · 2024
Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Papers in Europe PMC - 06Gresele P2 papers · 2024
Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Papers in Europe PMC - 07Megy K2 papers · 2024
Department of Haematology, University of Cambridge, Cambridge, UK.
Papers in Europe PMC - 08Abbas MT1 paper · 2025
Department of Cardiovascular Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Papers in Europe PMC - 09Al-Hebshi A1 paper · 2020
Pediatric Hematology Oncology, Prince Mohammed Bin Abdulaziz Hospital, Medina, SAU.
Papers in Europe PMC - 10Albalawi AM1 paper · 2020
Center for Genetics and Inherited Diseases, Taibah University Medina, Almadinah Almunawwarah , Saudi Arabia.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Bleeding disorder due to CalDAG-GEFI deficiency" OR "Bleeding disorder due to calcium- and DAG-regulated guanine exchange factor-1 deficiency" OR "BDPLT18" OR "RASGRP2 inherited bleeding disorder, platelet-type" OR "RASGRP2-related platelet disorder" OR "inherited bleeding disorder, platelet-type caused by mutation in RASGRP2" OR "platelet-type bleeding disorder 18"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Bleeding disorder due to CalDAG-GEFI deficiency" OR "Bleeding disorder due to calcium- and DAG-regulated guanine exchange factor-1 deficiency" OR "BDPLT18" OR "RASGRP2 inherited bleeding disorder, platelet-type" OR "RASGRP2-related platelet disorder" OR "inherited bleeding disorder, platelet-type caused by mutation in RASGRP2" OR "platelet-type bleeding disorder 18" OR "RASGRP2" OR "inherited bleeding disorder, platelet-type"
Recall-expansion terms: RASGRP2, inherited bleeding disorder, platelet-type
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:48:00.818Z